CTRI/2025/09/095370尚未招募Unknown
An In-vivo Study to determine the UV-A Protection Factor of Honasa Mamaearth Aqua Glow Hydrating Sunscreen Gel (Batch No: ME/AGS/19-0925/AB)
Honasa Consumer Ltd.1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2025年10月7日
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Change in Individual MED (iMED) score
研究概览
简要总结
This is the Invivo SPF test done as per UV-B protection ISO 24444 to determine the Sun Protection Factor
Test Product:
1. Honasa Mamaearth Aqua Glow Hydrating Sunscreen Gel
Done on 10 human volunteers. Duration: 3 Days
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18.00 Year(s) 至 65.00 Year(s)（—）
- 性别
- All
入选标准
- •Individual should have ITA angle in the range of 18 t0 40, 41 to 55, and greater than 56
- •Individuals free of any dermatological or systemic disorder which would interfere with the results, at the discretion of the investigator.
- •Individuals who have completed a preliminary medical history evaluation.
- •Individuals who have read, understood and signed an informed consent document relating to the specific study to which they are subscribing.
- •Individuals with no known abnormal response to sunlight.
排除标准
- •1.Individuals taking medication which in the opinion of the investigator would mask or interfere with the results.
- •2.Individuals with chronic skin allergies.
- •3.Individuals with suntan or sunburn.
- •4.Individuals with abnormal reaction to the sun.
- •5.Pregnant or lactating females.
- •6.Subjects accustomed to using sun beds.
- •7.Subjects who have participated in an SPF study within the last two months.
结局指标
主要结局
Change in Individual MED (iMED) score
时间窗: Day1, Day2, Day3
次要结局
- Not Applicable(Not Applicable)
研究者
Dr Robin Chugh
CCFT Laboratories
研究点 (1)
Loading locations...
相似试验
已完成
Unknown
SPF of Be Bodywise Lightest Mineral Sunscreen SPF50 plus.CTRI/2025/01/079638Mosaic Wellness Pvt Ltd10
尚未招募
不适用
Safety evaluation of cosmetic productsCTRI/2025/10/096020Quest Retails private Limited24
已完成
1 期
Study is designed to assess the safety and tolerability of ceralasertib at increasing doses in combination with other anti-cancer treatment in patients with advanced tumours2023-505006-41-00AstraZeneca AB100
尚未招募
不适用
skin Sensitization Potential of Kusum HSM-M and HSM-WCTRI/2025/10/096609Kusum Cosmetics50
招募中
1 期
Phase IB Study to Assess the Safety, Tolerability and Efficacy of PM14 in combination with Atezolizumab in Pretreated Patients with Selected Advanced Solid Tumors2023-509688-25-00Pharma Mar S.A.50